NASDAQ$JBIO
Jade Biosciences Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Aerovate Therapeutics' financial results for Q1 2024 were announced, highlighting the progress of the IMPAHCT trial and a cash runway into 2026.
Aerovate Therapeutics reported a net loss of $23.2 million for the first quarter of 2024. The company's cash, cash equivalents, and short-term investments totaled $99.3 million as of March 31, 2024, which is expected to fund operations into 2026. Topline data from the Phase 2b portion of the IMPAHCT trial is expected in June 2024, and enrollment continues in the Phase 3 portion.
- Topline data from the Phase 2b portion of the IMPAHCT trial of AV-101 for PAH is expected in June 2024.
- Enrollment is ongoing in the Phase 3 portion of the IMPAHCT trial of AV-101.
- Aerovate will present a poster with baseline characteristics of the Phase 2b portion of the IMPAHCT trial at the ATS 2024 Conference in May.
- The company's current cash runway is projected to last into 2026.
Headline financials
Revenue & EPS history
Aerovate · Revenue · Quarterly
$0
Forward guidance
Aerovate Therapeutics anticipates its cash, cash equivalents, and short-term investments will sustain operations into 2026, based on the current operating plan.
Tailwinds
- Cash runway extends into 2026.
- Focus on advancing AV-101 for PAH treatment.
- Ongoing enrollment in Phase 3 portion of IMPAHCT trial.
- Topline data from Phase 2b portion of IMPAHCT trial expected in June 2024.
- AV-101 targets cellular hyperproliferation in PAH.
Headwinds
- Reliance on successful clinical trial outcomes.
- Dependence on regulatory approvals.
- Potential for delays in clinical trials.
- Uncertainties in the development of AV-101.
- Risks associated with funding future operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2024
-1.6%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+2.6%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+24.6%
Q3 2023
Best reaction
-35.0%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.2% | +1.0% | +11.6% | |
| Q2 2025 | +0.1% | -0.5% | +4.9% | |
| Q1 2025 | +1.8% | -0.3% | -4.8% | |
| Q4 2024 | +0.4% | +0.4% | -85.8% | |
| Q3 2024 | +0.0% | -3.8% | -2.7% | |
| Q1 2024 | -2.8% | +3.7% | +16.1% | |
| Q4 2023 | -0.5% | +14.7% | -17.8% | |
| Q3 2023 | +24.6% | +27.6% | +68.5% | |
| Q2 2023 | -3.5% | -6.0% | -10.8% | |
| Q1 2023 | -7.6% | -12.2% | -19.8% | |
| Q4 2022 | +0.7% | +1.7% | +9.4% | |
| Q3 2022 | +0.6% | -7.1% | +32.9% | |
| Q2 2022 | -13.7% | -17.3% | -26.4% | |
| Q1 2022 | -6.3% | +0.7% | -5.9% | |
| Q4 2021 | +8.0% | -4.8% | -24.9% | |
| Q3 2021 | -35.0% | -33.8% | -42.7% | |
| Q1 2021 | +1.8% | -1.0% | +72.5% | |
| Q2 2021 | +1.8% | -1.0% | +72.5% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro